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SS peptideMitochondrial dysfunction has long been associated with neurodegenerative disease. Therefore, mitochon-
drial protective agents represent a unique direction for the development of drug candidates that can modify
the pathogenesis of neurodegeneration. This review discusses evidence showing that mitochondrial
dysfunction has a central role in the pathogenesis of Alzheimer's, Parkinson's and Huntington's diseases and
amyotrophic lateral sclerosis. We also debate the potential therapeutic efﬁcacy of metabolic antioxidants,
mitochondria-directed antioxidants and Szeto–Schiller (SS) peptides. Since these compounds preferentially
target mitochondria, a major source of oxidative damage, they are promising therapeutic candidates for
neurodegenerative diseases. Furthermore, we will brieﬂy discuss the novel action of the antihistamine drug
Dimebon on mitochondria.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Although the brain represents only 2% of the body weight, it
receives 15% of cardiac output and accounts for 20% of total body
oxygen consumption. This energy requirement is largely driven by
neuronal demand for energy to maintain ion gradients across the
plasma membrane that are critical for the generation of action
potentials. This intense energy requirement is continuous; even
brief periods of oxygen or glucose deprivation result in neuronal
death [1].
Mitochondria perform pivotal biochemical functions necessary for
homeostasis and are arbiters of cell death and survival, in addition to
being a source of ATP. They represent a convergence point for death
signals triggered by both extracellular and intracellular cues. As such,
the mitochondria sit at a strategic position in the hierarchy of cellular
organelles to either promote the healthy life of the cell or to terminate
it [2–4] (Fig. 1). Mitochondria are essential for neuronal function
because the limited glycolytic capacity of neurons makes them highly
dependent on aerobic oxidative phosphorylation (OXPHOS) for their
energetic needs [1,5,6] (Fig. 1). However, OXPHOS is a major source of
toxic endogenous free radicals, including hydrogen peroxide (H2O2),
hydroxyl (UOH) and superoxide (O2U−) radicals that are products of
normal cellular respiration. When the electron transport chain (ETC)
is inhibited, electrons accumulate in complex I and coenzyme Q,+1 216 368 8964.
ll rights reserved.where they can be donated directly to molecular oxygen to yield O2
U−
that can be further detoxiﬁed by the mitochondrial manganese
superoxide dismutase (MnSOD) producing H2O2 that, in turn, can be
converted to H2O by glutathione peroxidase (GPx). However, O2
U− in
the presence of nitric oxide (NOU), formed during the conversion of
arginine to citrulline by nitric oxide synthase (NOS), can lead to the
formation of peroxynitrite (ONOO−). Furthermore, H2O2 in the
presence of reduced transition metals can be converted to the toxic
productUOH via Fenton and/or Haber–Weiss reactions.
It is well recognized that reactive oxygen species (ROS) and
reactive nitrogen species (RNS) play a dual biological role since they
can be either harmful or beneﬁcial to living systems [7]. Beneﬁcial
effects of reactive species occur at low/moderate concentrations and
involve physiological roles in cellular responses to noxia, as for
example in defense against infectious agents and in the function of a
number of cellular signaling systems. One further beneﬁcial example
of ROS at low/moderate concentrations is the induction of amitogenic
response [7]. However, oxidative stress occurs if the amount of free
radical species produced overwhelms the cells' capacity (enzymatic
and non-enzymatic antioxidant defenses) to neutralize them,which is
followed by mitochondrial dysfunction and neuronal damage.
Reactive species generated by mitochondria have several cellular
targets, including mitochondrial components themselves (lipids,
proteins and DNA). The lack of histones in mitochondrial DNA
(mtDNA) and the diminished capacity for DNA repair render
mitochondria an especially vulnerable target of oxidative stress
events [8] (Fig. 1).
Fig. 1. The two faces of mitochondria. Besides the fundamental role of mitochondria in the generation of energy (ATP), these organelles are also the main producers of reactive
oxygen species (ROS). If ROS levels overwhelm the defense mechanisms of the cells, oxidative damage of proteins, lipids, and DNA occurs. Besides other constituents of the cells,
mitochondria are highly affected by oxidative damage leading to the impairment of ATP production. Other consequences of mitochondria impairment is the opening of the
permeability transition pore and release of pro-apoptotic factors that ultimately contributes to cell degeneration and death. Consequently, it is unsurprising that mitochondrial
oxidative damage is intimately involved in neurodegenerative diseases. Although ROS are traditionally viewed as toxic agents contributing to cellular pathology, emerging evidence
suggests that low/moderate levels of ROS are involved in survival and regulation pathways being critical in cellular homeostasis. H2O2, hydrogen peroxide; HO
U
, hydroxyl radical,
GPx, glutathione peroxidase; GRed, glutathione reductase; GSH, reduced glutathione; O2
U−, superoxide anion radical; SOD, superoxide dismutase.
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role in age-related neurodegenerative diseases. The recent realiza-
tion that mitochondria are at the intersection of the life and death of
a cell, particularly through the involvement ofmitochondrial damage
in a range of diseases, has made mitochondria a promising target for
drug discovery and therapeutic interventions. In this review, we will
discuss the close association betweenmitochondrial dysfunction and
neurodegeneration. Furthermore, we will evaluate several mito-
chondria-directed therapies namely metabolic antioxidants, mito-
chondria-targeted antioxidants Szeto–Schiller (SS) peptides, and
Dimebon.
2. Mitochondrial dysfunction and neurodegeneration
A major obstacle to the development of new therapies is our
inadequate knowledge of the etiology of the neurodegenerative
diseases. Although genetic mutations account for a small number of
these disorders, the majority of cases appear to be sporadic in nature.
Many lines of evidence suggest that mitochondria have a central role
in aging-related neurodegenerative diseases. Indeed, mitochondrial
dysfunction has been described in several neurodegenerative dis-
orders including Alzheimer's disease (AD), Parkinson's disease (PD),
Huntington's disease (HD) and amyotrophic lateral sclerosis (ALS).
AD is the most common cause of dementia among older people.
This degenerative brain disease typically begins with a subtle decline
in memory and progresses to global deterioration in cognitive andadaptive functioning. The neuropathological features associated with
the disease include the presence of extracellular senile plaques,
intracellular neuroﬁbrillary tangles (NFT) and the loss of basal
forebrain cholinergic neurons that innervate the hippocampus and
the cortex. NFT are formed from paired helical ﬁlaments composed of
neuroﬁlaments and hyperphosphorylated tau protein. Senile plaques
are formedmostly from the deposition of the amyloid-β (Aβ) peptide,
a 39–43 amino acid peptide generated through the proteolytic
cleavage of the amyloid-β precursor protein (AβPP) by the β- and
γ-secretases. Accumulating evidence indicates that mitochondrial
abnormalities and oxidative damage are early events in AD [9,10].
Indeed, Manczak and colleagues [11] found an increase in H2O2 and a
decrease in cytochrome oxidase activity in young Tg2576 mice prior
to the appearance of Aβ plaques suggesting that oxidative stress is an
early event in AD pathophysiology.
Evidence for mitochondrial dysfunction in AD pathogenesis comes
from impaired activity of three tricarboxylic acid cycle (TCA)
complexes, pyruvate dehydrogenase, isocitrate dehydrogenase and
α-ketoglutarate dehydrogenase, observed in postmortem AD brain
and ﬁbroblasts [12,13]. Similarly, reduced respiratory chain activities
in complexes I, III and IV have been found in platelets and lym-
phocytes from AD patients and postmortem brain tissue [14–17].
Several in vitro studies corroborate the idea that mitochondria are
key players in AD. First, Aβ requires functional mitochondria to
induce toxicity [18]. Previous studies showed that Aβ1–40 induced a
signiﬁcant increase in H2O2 production in brain mitochondria iso-
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tinuous intracerebroventricular infusion of both Aβ25–35 and Aβ1–40
for up to 14 days stimulated H2O2 generation in isolated neocortex
mitochondria [21].
In addition, an active γ-secretase complex in rat brain mitochon-
dria was identiﬁed [22]. Being composed of nicastrin (NCT), anterior
pharynx-defective-1 (APH-1) and presenilin enhancer protein 2
(PEN2), this γ-secretase complex cleaves, among other substrates,
AβPP generating Aβ and AβPP intracellular domain. Furthermore,
AβPP was detected in mitochondrial membranes of PC12 cells bearing
the Swedish double mutation in AβPP gene [23]. Both Aβ and AβPP
have strong copper (Cu)-reductase activity, generating Cu+ from
Cu2+. This reaction produces H2O2 as a by-product [24]. In addition to
Cu2+, Aβ also binds zinc (Zn2+) and iron (Fe3+) potentiating oxi-
dative stress [24]. Aβ also potentiates the opening of the mitochon-
drial permeability transition pore (PTP) induced by Ca2+ [25,26]. It
was reported that the interaction of cyclophilin D, an integral part of
the PTP, with mitochondrial Aβ potentiates mitochondrial, neuronal
and synaptic stress [27]. It was also observed that cyclophilin D
deﬁciency substantially improves learning and memory and synaptic
function in an ADmouse model and alleviates Aβ-mediated reduction
of long-term potentiation [27]. Recently, we showed that sporadic AD
ﬁbroblasts present alterations in mitochondria morphology and
distribution [28]. We demonstrated that these mitochondrial abnor-
malities are due to a decrease in dynamin-like protein 1 (DLP1), a
regulator of mitochondrial ﬁssion and distribution [28]. Further, we
reported that overproduction of Aβ causes abnormal mitochondrial
dynamics including morphology, distribution and function via
differential modulation of mitochondrial ﬁssion/fusion proteins
[29]. Similarly, Cho and collaborators [30] found that NOU produced
in response to Aβ triggers mitochondrial ﬁssion, synaptic loss and
neuronal damage, in part via S-nitrosylation of DLP1. Studies have also
shown increased autophagic degradation of mitochondria in AD brain
[31,32].
PD is the second most common neurodegenerative disease and
affects individuals over the age of 65 years. This disease is
characterized by degeneration and death of dopaminergic neurons
in the pars compacta of the substantia nigra and by the presence of
Lewy bodies. Dopaminergic neurons in the substantia nigra operate in
a pathway that controls voluntary movement. Death of dopamine-
containing neurons results in the inability to coordinate movement. It
is well established that oxidative stress and mitochondrial dysfunc-
tion are associated with the degeneration of dopaminergic neurons in
PD. Mitochondria were demonstrated to be one of the direct targets of
α-synuclein during the pathogenesis of PD [33]. α-Synuclein
accumulates in the mitochondria of the striatum and substantia
nigra of PD patients impairing mitochondrial complex I activity and
causing oxidative stress. Moreover, the neurotoxin 1-methyl-4-
phenylpyridium (MPP+), which is commonly used to induce
parkinsonism in animal models, inhibits mitochondrial complex I
resulting in the generation of free radicals [34], whereas the
overexpression of Akt prevents ROS increase and apoptosis [35]. It
has been previously shown that brain mitochondria isolated from
rotenone-treated rats, a model of PD, presented an impaired
respiratory chain associated with an increased O2
U− production and
probability of PTP opening [36]. It was also shown that organotypic
striatal slice cultures exposed to 1 mM rotenone presented a
signiﬁcant increase in lactate dehydrogenase activity and O2
U− and
NOU levels [37]. Furthermore, Dahm and colleagues [38] reported that
the S-nitrosation of mitochondrial complex I, a common situation in
PD, was correlated with a signiﬁcant loss of activity and an increased
O2
U− production from complex I. These ﬁndings point to a signiﬁcant
role for complex I S-nitrosation and consequent dysfunction during
nitrosative/oxidative stress in disorders such as PD.
Domingues et al. [39] showed that mitochondrial-DNA-depleted
cells (rho0) compromised at the mitochondrial and ubiquitin–proteasomal system (UPS) levels presented with an alteration of the
oxidative status. In parental cells (rho+), MPP+ induced a clear
inhibition of complex I activity and an increase in the levels of
ubiquitinylated proteins. Moreover, MPP+ induced a decrease in 20S
chymotrypsin-like and peptidyl–glutamyl peptide hydrolytic-like
proteolytic activities and an increase in ROS [39]. These results
suggest that mitochondrial alterations lead to an imbalance in cellular
oxidative status inducing proteasomal deregulation. This may
exacerbate protein aggregation and consequently engender degener-
ative events. It was also shown that, under basal conditions, PD cybrid
lines (cells in which endogenous mtDNA from PD was expressed
within human teratocarcinoma cells) produce less ATP, more LDH
release, depolarized mitochondria, less mitochondrial cytochrome c
and higher caspase 3 activity [40]. Mitochondrial dysfunction can also
induce α-synuclein oligomerization via ATP depletion-driven micro-
tubule depolymerization and via ROS increase-driven protein oxida-
tion [41]. Petit-Paitel and colleagues [42] demonstrated that both
cytosolic and mitochondrial glycogen synthase kinase-3β (GSK-3β)
were involved in mitochondrial dysfunction and neuronal cell death
in MPP+-treated neurons. Further, it has been shown that defects in
PTEN induced kinase 1 (PINK1), a mitochondrial Ser/Thr kinase,
causes mitochondrial dysfunction, proteasomal deﬁcit and α-synu-
clein aggregation in cell culture models of PD [43]. Recently, Moisoi
and collaborators [44] demonstrated that the loss of HtrA2 resulted in
transcriptional upregulation of nuclear genes characteristic of the
integrated stress response, including the transcription factor CHOP,
selectively in the brain. The same authors also showed that the loss of
HtrA2 results in the accumulation of unfolded proteins in the
mitochondria, defective mitochondrial respiration and enhanced
production of ROS that contributed to the induction of CHOP
expression and to neuronal cell death [44].
HD is an autosomal-dominant disease caused by an abnormal
expanded polyglutamine repeat in the huntingtin (htt) protein, which
leads to the degeneration of the neurons in the striatum and cortex. A
number of studies indicate thatmitochondrial dysfunction is central to
the pathogenesis of HD. Reduction of the activities of complexes II, III
and IV has been observed in the caudate and putamen of HD patients
[45]. A recent study showed increased glucose utilization relative to
oxygen utilization in the striatum of early HD patients [46]. Chen and
collaborators [47] also observed mitochondrial abnormalities and
oxidative damage in the peripheral blood of HD patients. Moreover,
Lim and co-workers [48] reported that mutant htt expression induced
PTP opening and disruption of mitochondrial Ca2+ homeostasis.
Similar results were obtained in mitochondria isolated from cells
expressingmutant htt [49], suggesting thatmitochondrial dysfunction
plays a central role in HD pathogenesis. Mitochondrial NAD+-linked
state 3 respiration and complex I activity were found to be
compromised in the cerebral cortex of the 3-nitropropionic acid (3-
NP)-induced rat model of HD [50]. Kumar and Kumar [51] reported
that 3-NP administration for 14 days signiﬁcantly induced HD like
symptoms in rats as indicated by change in body weight, locomotor
activity, rotarod activity performance, oxidative damage (elevated
levels of lipid peroxidation, nitrite concentration and depletion of
antioxidant enzyme levels) and impairment of mitochondrial com-
plexes I, II, II and IV in striatum, cortex and hippocampus. It was also
reported that PC12 cells treated with 3-NP present high levels of H2O2
and a decline in ATP levels, these effects being prevented by Bcl2
overexpression [52]. However, Kim and Chan [53] report that O2−
U is
involved in excitotoxicity and DNA fragmentation in striatal vulner-
ability in mice after treatment with the mitochondrial toxin 3-NP.
Recently, it was suggested that mtDNA damage is an early biomarker
for HD-associated neurodegeneration supporting the hypothesis that
mtDNA lesions might contribute to the pathogenesis observed in HD
[54]. Orr and colleagues [55] reported that speciﬁc N-terminal mutant
htt fragments, before they form aggregates, would impair mitochon-
drial function directly.
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resulting in weakness, paralysis and subsequent death. Some 90% of
cases are sporadic, i.e., unknown cause, and 10% of cases are familial.
In 20% of the familial cases of ALS, motor neuron loss is related to
mutations of the Cu/Zn superoxide dismutase (SOD1) gene. Mutant
SOD1 has been shown to exert deleterious effects through a gain of
function rather than a loss of activity [56]. Additionally, the presence
of mutant SOD1 within motor neuron causes alterations of the
mitochondrial respiratory chain [57], speciﬁcally in mitochondrial
complexes II and IV [56]. Indeed, Zimmerman and colleagues [58]
reported that mitochondrial-produced O2−
U plays a critical role in
mutant SOD1-mediated neuronal toxicity. A recent study also shows
that SOD1 increases the vulnerability of mitochondria and perturbs
Ca2+ homeostasis in SOD1G93A mice, a mouse model of ALS [59].
Further, it was reported that mitochondrial dysfunction in
SOD1G93A-bearing astrocytes promotes motor neuron degeneration,
this effect being prevented by mitochondrial-targeted antioxidants
[60]. Kawamata and collaborators [61] reported that the mitochon-
drial lysyl-tRNA synthetase (mitoKARS) interacted with mutant SOD1
contributing to mitochondrial dysfunction in ALS. There is evidence of
abnormal structure and number of mitochondria and compromised
mitochondrial function in ALS motor neurons and skeletal muscle.
This is corroborated by ﬁndings of altered respiratory chain enzyme
activities and CNS energy hypometabolism in the spinal cord and
motor cortex of ALS patients [62–64].
The evidence presented above clearly indicates that mitochondrial
abnormalities are intimately involved in the pathophysiology of
neurodegenerative diseases.
3. Mitochondrial-directed therapies
The discovery that mitochondrial dysfunction underlies the
pathogenesis of many neurodegenerative diseases has opened a
window for new therapeutic strategies aimed at preserving/amelio-
rating mitochondrial function. In nearly all cases wheremitochondrial
dysfunction contributes to disease, a major cause of damage is
overproduction of ROS by mitochondria, either directly or as a
secondary consequence of other malfunctions [1,3].
3.1. Metabolic antioxidants
Metabolic antioxidants are involved in cellular energy production
and act as cofactors of several metabolic enzymes (Fig. 2). The
creatine/phosphocreatine system, regulated by mitochondrial crea-
tine kinase, plays an important role in maintaining energy balance in
the brain. The presence of this energy buffer system keeps the ATP/
ADP ratio high at subcellular sites where ATP is needed. This also
minimizes the loss of adenosine nucleotides, which causes cellular
dysfunction. Recently, it was shown that the progression of mild
cognitive impairment (MCI) to dementia is associated with a decline
of N-acetyl aspartate and creatine [65]. Furthermore, creatine
supplementation was found to be neuroprotective in several in vitro
and in vivo studies. Chronic administration of creatine was shown to
signiﬁcantly increase survival, tyrosine hydroxylase immunoreactive
ﬁber density and soma size of dopaminergic neurons in mesence-
phalic cultures by protecting against neurotoxic insults induced by
serum and glucose deprivation, MPP+ and 6-hydroxydopamine
[66,67]. It has been shown that creatine protects against dopamine
loss and attenuates neuron loss in the substantia nigra of mice treated
with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) [68]. The
same group also showed that oral creatine administration reduces the
size of ischemic brain infarctions in mice [69] and attenuates striatal
excitotoxic lesions produced by N-methyl-D-aspartate (NMDA) [70].
In addition, creatine was shown to affect the morphogenesis of
dendritic spines and synapses [71]. Oral administration of creatine
produces a dose-dependent improvement in motor performance andextends survival in G93A transgenic ALS mice, where it protects
against loss of both motor and substantia nigra neurons [72]. Creatine
administration protects against glutamate and Aβ toxicity in rat
hippocampal neurons [73]. Creatine is also beneﬁcial in animal
models of traumatic brain injury and cerebral ischemia [74,75]. The
success of creatine in experimental studies led to clinical trials in
neurodegenerative diseases, including PD, HD and ALS. In a small pilot
trial, creatine improved patient mood but had no effect on the overall
Uniﬁed Parkinson's Disease Rating Scale (UPDRS) or dopamine
transporter single photon emission computed tomography (SPECT)
[76]. A recent study shows that long-term creatine supplementation is
safe in aged PD patients [77]. It has also been shown that creatine
treatment of HD patients is safe, tolerable, bioavailable in the brain
and reduces serum 8-hydroxy-2′-deoxyguanosine levels, an indicator
of oxidative injury to DNA [78]. However, Verbessem and collabora-
tors [79] reported that 1 year of creatine treatment, at a dose that
could improve functional muscle capacity in healthy subjects and
patients with neuromuscular disease (5 g/day), did not improve
functional, neuromuscular and cognitive status in HD patients.
Similarly, a previous clinical trial did not ﬁnd a signiﬁcant effect of
creatine on ALS patients [80]. Despite the positive effects obtained in
in vitro and animal studies, clinical trials do not support creatine
supplementation for the treatment of neurodegenerative conditions.
Lipoic acid (LA) is a coenzyme for mitochondrial pyruvate
dehydrogenase and α-ketoglutarate dehydrogenase. Furthermore, it
is a powerful antioxidant and can recycle other antioxidants, such as
vitamins C and E and glutathione. Hager and collaborators [81,82]
reported that the administration of 600 mg LA/day to AD patients
promoted stabilization of cognitive measures. We have recently
shown that LA and/or N-acetyl cysteine (NAC; an antioxidant and
glutathione precursor) decrease mitochondrial-related oxidative
stress in ﬁbroblasts isolated from AD patients [83]. Abdul and
Butterﬁeld [84] investigated whether pretreatment of cortical
neurons with LA and acetyl-L-carnitine-carnitine (ALCAR; a com-
pound that acts as an intracellular carrier of acetyl groups across the
inner mitochondrial membrane) protected cortical neuronal cells
from 4-hydroxy-2-nonenal-mediated oxidative stress and neurotox-
icity. This study showed crosstalk between phosphoinositol-3 kinase
(PI3K), PKG and ERK1/2 pathways in cortical neurons that contrib-
uted to ALCAR and LA-mediated pro-survival signaling mechanisms
[84]. Suh and collaborators [85] reported that old rats injected with LA
showed improvement in glutathione redox status of both cerebral and
myocardial tissues when compared with control rats. They also
showed that LA produced signiﬁcantly increased survival in both R6/2
and N171-82Q transgenic mouse models of HD [86]. A recent study
also showed that chronic dietary LA reduces deﬁcits in hippocampal
memory of aged Tg2576 mice [87]. Aliev and collaborators [88]
reported that LA and ALCAR supplementation signiﬁcantly reduced
the number of severely damaged mitochondria and increased the
number of intact mitochondria in the hippocampus of aged rats. A
recent study also showed that ApoE4 mice fed ALCAR and LA have
some improvement in cognitive performance [89]. Bianchetti and
collaborators [90] performed an open study to evaluate the effect of
ALCAR (2 g/day orally for 3 months) in association with donepezil or
rivastigmine in 23 patients with mild AD who had not responded to
treatment with an acetylcholinesterase inhibitor (AChEI). Clinical
effects were evaluated by assessing cognitive functions, functional
status and behavioral symptoms. The response rate, which was 38%
after AChEI treatment, increased to 50% after the addition of ALCAR,
indicating that the combination of these two drugs may be a useful
therapeutic option in AD patients. However, this study does not
identify the possible mechanism of action by which the two
treatments synergize. Furthermore, the efﬁcacy of ALCAR in MCI
and mild AD was investigated with a meta-analysis of double-blind,
placebo-controlled prospective, parallel group comparison studies of
at least 3months duration [91]. The authors reported beneﬁcial effects
Fig. 2.Mitochondrial-directed therapies. Metabolic antioxidants (creatine, α-lipoic acid, N-acetyl-carnitine and coenzyme Q10) are involved in cellular energy production and act as
cofactors of several metabolic enzymes. Additionally, they have also potent antioxidant actions avoiding damage of lipids, proteins and DNA.Mitochondria-targeted antioxidants and
SS peptides selectively accumulated into mitochondria, a major source of reactive oxygen species (ROS) protecting against oxidative damage of mitochondrial and cellular
components. Dimebon binds to NMDA receptors on the outside of the cell and decreases glutamate inﬂux. It also binds Ca2+ channels and prevents an inﬂux of Ca2+ from entering
the cell. Recent evidence shows that Dimebon stabilizes mitochondria by preventing the opening of the permeability transition pore.
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whether ALCAR is clinically effective in the treatment of people with
dementia, Hudson and Tabet [92] analyzed and compared 11 double-
blind randomized trials involving people with dementia, in which
treatment with ALCAR was compared with a placebo group. The
analysis indicated a beneﬁt of ALCAR on cognitive global impression,
but there was no evidence of improvement using objective assess-
ments in any other area of outcome. Furthermore, the authors
emphasized that given the large number of comparisons the statistical
signiﬁcance may result from chance.
CoQ10 serves as an important cofactor of the ETC, where it accepts
electrons from complexes I and II. CoQ10 acts as a potent antioxidant,
blocks apoptosis by inhibiting the PTP and is a co-factor of
mitochondrial uncoupling proteins [93]. In vitro studies showed that
CoQ10 pre-treatment prevents a decrease in mitochondrial trans-
membrane potential and reduces mitochondrial ROS generation [94].
Furthermore, it was shown that CoQ10 treatment counteracts brain
mitochondrial alterations induced byAβ1–40 [19]. Previous studies also
showed that CoQ10 protects against paraquat- and rotenone-induced
mitochondrial dysfunction and neuronal death in human neuroblas-
toma cells (SHSY-5Y) and primary rat mesencephalic neurons,
respectively [95,96]. CoQ10 also protects against iron-induced
apoptosis in dopaminergic neurons [97] and exerts anti-amyloido-
genic effects by destabilizing preformed Aβﬁbrils in vitro [98]. Further,
CoQ10 protects SHSY-5Y cells against Aβ toxicity through inhibition of
PTP opening [99]. Similarly, pretreatment of neuronal cellswith CoQ10
maintains mitochondrial membrane potential during oxidative stress
and reduces the amount of mitochondrial ROS generation [94].
Moreover, several studies have been conducted using CoQ10 in in
vivomodels. Recently, Yang and collaborators [100] tested the effect of
CoQ10 on Aβ in aged transgenic mice overexpressing Alzheimer
presenilin 1-L235P. The treatment, feeding the transgenic mice withCoQ10 for 60 days (1,200 mg/kg/day), partially attenuated Aβ
overproduction and intracellular Aβ deposits in the cortex of the
transgenicmice comparedwith the untreated age-matched transgenic
mice. Meanwhile, an increased oxidative stress reaction was demon-
strated by elevated levels of malondialdehyde (MDA) and decreased
activity of SOD in the transgenic mice relative to the wild-type mice;
supplementation with CoQ10 partially decreased the MDA level and
upregulated the activity of SOD [100]. Sharma and collaborators [101]
reported that the administration of CoQ10 increased complex I activity
and partially improved motor performance in weaver mutant mice.
The same authors reported that direct exposure to rotenone reduced
CoQ10, complex I activity and mitochondrial membrane potential in
SK-N-SH cells. Rotenone-induced down-regulation of complex I
activity was attenuated by CoQ10 treatment, suggesting that complex
I might be down-regulated due to depletion of CoQ10 in the brain
[101]. Further, dietary administration of CoQ10 results in signiﬁcant
protection in a chronic MPTP model [102]. It was also shown that
administration of CoQ10 exerted a therapeutic beneﬁt in a dose-
dependent manner in R6/2 mice, a model of HD [103]. Stack and
collaborators [104] evaluated the effects of combinedminocycline and
CoQ10 treatment in the R6/2 mouse. Combined minocycline and
CoQ10 therapy provided an enhanced beneﬁcial effect, ameliorating
behavioral and neuropathological alterations; minocycline and CoQ10
treatment signiﬁcantly extended survival and improved rotarod
performance to a greater degree than either minocycline or CoQ10
alone. In addition, combined treatment attenuated gross brain
atrophy, striatal neuron atrophy and htt aggregation in the R6/2
mice [104], suggesting that this may offer therapeutic beneﬁt to
patients suffering from HD.
Altogether these results suggest that the delivery of antioxidants
that protect mitochondria and reduce oxidative stress-related events
represent a promising therapeutic approach for the treatment of
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somewhat disappointing. A signiﬁcant problem with the majority of
clinical studies is that they have been conducted in patient
populations who already have a neurodegenerative condition. This
makes it difﬁcult to assess the full potential of antioxidants to help
prevent neurodegeneration. However, the broad occurrence of the
disease, the limited regenerative nature of the CNS and the fact that
the diagnosis often does not occur until late in disease progression
suggest that the ideal antioxidant should be used as a prophylactic
treatment in the population.
3.2. Mitochondria as a target for antioxidants and SS peptides
A major limitation to antioxidant therapy in treating age-related
neurodegenerative diseases has been the inability to enhance the
antioxidant levels within mitochondria. However, in the last several
years, considerable progress has been made in developing mitochon-
dria-targeted antioxidants (i.e., antioxidants that are selectively
accumulated in mitochondria) (Fig. 2). Several have been developed
by conjugating the lipophilic triphenylphosphonium (TPP+) cation to
an antioxidant moiety, such as coenzyme Q (MitCoQ) and α-
tocopherol (MitoVitE) [105]. This approachmakes use of the potential
gradient across the mitochondrial inner membrane. As a result of the
proton gradient, a negative potential to 150 to 180 mV is generated
across the inner membrane. Lipophilic cations may therefore
accumulate 100- to 1000-fold in mitochondria. In fact, MitoVitE is
taken up by mitochondria ≈80-fold more than vitamin E [106]. The
authors observed that MitoVitE was far more effective in protecting
mitochondria against oxidative stress than vitamin E itself. Further-
more, it has been shown that MitoVitE is 800-fold more potent than
idebenone, a CoQ10 analog, in protecting against GSH depletion in
cultured ﬁbroblasts from patients with Friedreich ataxia and is 350-
foldmore potent than trolox, a vitamin E analog [107]. Recently, it was
shown that MitVitE mitigates ethanol-induced accumulation of
intracellular oxidants and counteracts suppression of glutathione
peroxidase/glutathione reductase functions, protein expression of γ-
glutamylcysteine synthetase and total cellular glutathione levels in
cerebellar granule cells [108].
MitoQ is a promising therapeutic antioxidant that has been
successfully targeted to mitochondria. Coenzyme Q (or ubiquinone)
is a respiratory chain component that accepts electrons from
complexes I or II, to form the reduced product ubiquinol, which
donates electrons to complex III. The ubiquinone pool in vivo exists
largely in a reduced ubiquinol form, acting as an antioxidant and a
mobile electron transfer. Ubiquinol has been reported to function as
an antioxidant by donating a hydrogen atom from one of its hydroxyl
groups to a lipid peroxyl radical, thereby decreasing lipid peroxidation
within the mitochondrial inner membrane [109]. James and collea-
gues [110] reported that the favored orientation of MitoQ is with the
TPP+ moiety near the membrane surface and the ubiquinone
penetrating into the membrane core. This orientation enables the
ubiquinone moiety to access the membrane core to act as a chain
breaking antioxidant and allows recycling of MitoQ to its ubiquinol
form via reduction by complex II. The ubiquinol derivative thus
formed is an effective antioxidant that prevents lipid peroxidation and
protects mitochondria from oxidative damage [111]. However, MitoQ
cannot be oxidized by complex III explaining why it does not function
as an electron carrier in mitochondrial respiration [112].
Recently, the effects of MitoQ on mitochondria in several in vitro
cell models were tested [107,113–115]. In cultured ﬁbroblasts from
Friedreich ataxia patients, MitoQ prevented cell death known to be
caused by endogenous oxidative stress [107]. Low concentrations of
MitoQ selectively inhibited serum deprivation-induced apoptosis in
PC12 cells [114]. MitoQ reduces ROS formation and preserves
mitochondrial function after glutathione depletion, even in cells
lacking mtDNA [116]. These studies suggest that MitoQ may reducefree radicals, decrease oxidative damage and maintain mitochondrial
function. Since oxidative damage is intimately involved in the
pathophysiology of AD, there is strong interest in determining
whether mitochondria-targeted antioxidants can decrease oxidative
damage in the neurons of AD patients [117]. In phase I trials, MitoQ
showed good pharmacokinetic behavior with oral dosing at 80 mg
(1 mg/kg), resulting in a plasma Cmax=33.15 ng/ml and Tmax=1 h.
This formulation is now in phase II clinical trials for PD and Friedreich
ataxia (Antipodean Pharmaceuticals Inc., San Francisco, CA).
There is a novel class of small cell permeable peptide antioxidants
that target mitochondria in a potential-independent manner (Fig. 2).
The structural motif of these Szeto–Schiller (SS) peptides centers on
alternating aromatic residues and basic amino acids [118]. SS-31 has a
remarkable potency that can be explained by its extensive cellular
uptake and selective partitioning into mitochondria. Intracellular
concentrations of [3H]SS-31 were 6-fold higher than extracellular
concentrations. Studies using isolatedmitochondria revealed that [3H]
SS-31 was concentrated 5000-fold in the mitochondrial fraction. By
concentrating in the inner mitochondrial membrane, SS-31 became
localized to the site of ROS production and protected against
mitochondrial oxidative damage and against further ROS production
[119]. SS-31 protects neuronal cells against tert-butyl-hydroperoxide-
induced mitochondrial depolarization and apoptotic cell death by
reducing intracellular ROS, decreasing markers of apoptotic cell death
and caspase activity [120]. It decreases mitochondrial ROS production
and inhibits PTP and mitochondrial depolarization in isolated
mitochondria [119]. Daily injections of SS-31 intoG93A SOD1mutants,
an animalmodel of ALS, before onset of symptoms, lead to a signiﬁcant
increase in survival and improvement of motor performance [121].
Recently, Yang and collaborators [122] examined the ability of SS-31
and SS-20 to protect against MPTP neurotoxicity in mice. SS-31
produced complete dose-dependent protection against loss of dopa-
mine and its metabolites in the striatum as well as loss of tyrosine
hydroxylase immunoreactive neurons in substantia nigra. SS-20,
which does not possess the intrinsic ability to scavenge ROS, also
demonstrated signiﬁcant neuroprotective effects on dopaminergic
neurons ofMPTP-treatedmice. Both SS-31 and SS-20were very potent
in preventingMPP+-induced cell death in cultured dopaminergic cells
[122]. Studies with isolatedmitochondria showed that both SS-31 and
SS-20 prevented MPP+-induced inhibition of oxygen consumption
and ATP production and mitochondrial swelling [122]. These ﬁndings
provide strong evidence that these neuroprotective peptides, which
target both mitochondrial dysfunction and oxidative damage, are
promising for the treatment of neurodegenerative disorders.
3.3. Dimebon
The antihistamine drug Dimebonwas ﬁrst used to treat allergies in
Russia in the early 1980s. Recently, Dimebon has been proposed to be
useful for treating neurodegenerative disorders [123] (Fig. 2). Results
of the ﬁrst pivotal clinical trial of Dimebon in AD showed that this
drug improved the clinical course of the disease [124]. In this
randomized, double-blind, placebo-controlled trial of 183 patients
with mild-to-moderate AD, patients treated with Dimebon experi-
enced statistically signiﬁcant improvements compared to placebo in
all of the key aspects of the disease: memory and thinking, activities of
daily living, behavior and overall function. After both 6 months and a
full year of treatment, Dimebon-treated patients performed signiﬁ-
cantly better than placebo-treated patients in all key measures of the
disease [124]. A phase III trial of Dimebon in AD treatmentwill soon be
initiated. Dimebon also demonstrated efﬁcacy in a phase II trial with
HD patients conducted by Medivation and the Huntington Study
Group (DIMOND). Despite extremely encouraging results in clinical
trials, the mechanisms responsible for the beneﬁcial actions of
Dimebon remain poorly understood. Previous reports show that
Dimebon is an inhibitor of NMDA receptors [125–127] and voltage-
218 P.I. Moreira et al. / Biochimica et Biophysica Acta 1802 (2010) 212–220gated Ca2+ channels [127,128]. A previous study also showed that
Dimebon blocks opening of the mitochondrial PTP induced by Aβ25–35
and MPP+ [129]. Together these studies suggest that the clinical
beneﬁts exerted by Dimebon may be due to its ability to stabilize
neuronal Ca2+ homeostasis and mitochondrial function. Currently,
the scientiﬁc community is actively investigating the mode of action
of Dimebon in neurodegenerative diseases.
4. Conclusions
Many lines of evidence show that mitochondrial abnormalities and
oxidative damage play a central role in the pathogenesis of several
neurodegenerative diseases. Therefore, the development of
approaches to prevent or decrease mitochondrial dysfunction may
provide therapeutic efﬁcacy. The metabolic antioxidants and mito-
chondria-directed antioxidants and SS peptides have proved to be
effective in pre-clinical and small clinical studies substantiating their
promise. Furthermore, combinations of antioxidants may be more
effective than the use of single agents. However, larger clinical trials
with larger numbers of participants are needed to provide more
deﬁnitive information on the therapeutic efﬁcacy of these com-
pounds. The novel therapeutic candidate Dimebon is effective in
ameliorating the cognitive decline in AD and HD patients. However,
its mechanism of action remains unclear highlighting the need for
more research with this agent, particularly in animal models. In the
future, mitochondrial-directed therapies will open new avenues for
themanipulation ofmitochondrial function providing protection from
neurodegenerative diseases.
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